Journals / Türk Oftalmoloji Dergisi / 2019 / Cilt: 49 - Sayı: 4

The Utility of Colistin in Multiple Drug-Resistant Pseudomonas aeruginosa Bacterial Keratitis in a Kaposi’s Sarcoma Patient

Kaposi Sarkomlu Bir Hastadaki Çoklu İlaç Direncine Sahip Pseudomonas aeruginosa Bakteriyel Keratitinde Kolistin Etkisi

Pages
220–223
Publication Date
2022-11-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this report, we aimed to stress the utility of colistin in multiple drug-resistant P. aeruginosa bacterial keratitis in a Kaposi’s sarcoma patient

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 71-year-old male patient presented with decreased visual acuity, redness, and discharge in his right eye for 5 days.
📊
Key Findings & Data:Slit-lamp examination revealed severe hypopyon and an extensive corneal ulcer with surrounding infiltrate, which extended to the deep stroma.
💡
Conclusion & Impact:In this report, we aimed to stress the utility of colistin in multiple drug-resistant P. aeruginosa bacterial keratitis in a Kaposi’s sarcoma patient
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 71-year-old male patient presented with decreased visual acuity, redness, and discharge in his right eye for 5 days. He had undergone evisceration of his left eye several years earlier. Before presentation, he had received chemotherapeutic agents for Kaposi’s sarcoma of the scalp. Slit-lamp examination revealed severe hypopyon and an extensive corneal ulcer with surrounding infiltrate, which extended to the deep stroma. Microbiological evaluation identified the causative agent to be multiple drug-resistant Pseudomonas aeruginosa. Based on culture and susceptibility results, the patient was started on topical colistin 0.19% instilled hourly. Complete resolution of keratitis with residual corneal scarring was observed. In recent years, there has been an increase in drug resistance in P. aeruginosa keratitis. The lack of new antimicrobial agents against these resistant strains has led clinicians to reconsider colistin, which is an old drug. In this report, we aimed to stress the utility of colistin in multiple drug-resistant P. aeruginosa bacterial keratitis in a Kaposi’s sarcoma patient

Özet

Yetmiş bir yaşındaki erkek hasta, sağ gözünde 5 gündür devam eden görme azlığı, kızarıklık ve çapaklanma şikayeti ile başvurdu.Sol göz yıllar öncesinde evisserasyon cerrahisi geçirmişti. Hastanın mevcut durumu öncesinde skalp Kapasi sarkomu için kemoterapikullanım hikayesi bulunmaktaydı. Biyomikroskobik muayenede, etrafında stromaya uzanan infiltrasyon bulunan, hipopyonla birliktelikgösteren geniş korneal ülser mevcuttu. Mikrobiyolojik inceleme sonucu etken çoklu ilaç direncine sahip Pseudomonas aeruginosa olaraktanımlandı. Kültür antibiyogram sonucuna göre hastaya %0,19 konsantrasyonunda topikal kolistin, saat başı damla olarak başlandı.Keratitin, rezidü korneal skar bırakarak tamamen düzeldiği izlendi. Son yıllarda, P. aeruginosa keratitinde giderek artan bir ilaç direnciortaya çıkmaktadır. Dirençli ajanlara karşı yeni geliştirilen antimikrobiyellerin bulunmaması, klinisyenleri eski bir ilaç olan kolistinitedavide yeniden kullanmaya yöneltmiştir. Bu olgu sunumu ile Kaposi sarkomlu bir hastada gelişen bakteriyel keratitin tedavisindekolistinin yerini vurgulamayı istedik.

🔖

Cite This Article

TUNGER, A., EĞRİLMEZ, S., DAĞ, M. Y., SELVER, Ö. B., HASANOV, S. (2022). The Utility of Colistin in Multiple Drug-Resistant Pseudomonas aeruginosa Bacterial Keratitis in a Kaposi’s Sarcoma Patient. Türk Oftalmoloji Dergisi, Cilt: 49 - Sayı: 4, 220–223. https://ajindex.com/articles/655130

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214-221
  2. Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR. Pseudomonas aer-uginosa keratitis: outcomes and response to corticosteroid treatment. Invest Ophthalmol Vis Sci. 2012;53:267-272
  3. Ly CN, Pham JN, Badenoch PR, Bell SM, Hawkins G, Rafferty DL, McClellan KA. Bacteria commonly isolated from keratitis specimens retain susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Experiment Ophthalmol. 2006;34:44-50
  4. Jhanji V, Sharma N, Satpathy G, Titiyal J. Fourth-generation fluoroquinolone resistant bacterial keratitis. J Cataract Ref Surg. 2007;33:1488-1489
  5. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone anti- biotics. Cornea. 2009;28:68-72
  6. Oldenburg CE, Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Borkar DS, Ray KJ, Zegans ME, McLeod SD, Porco TC, Lietman TM, Acharya NR. Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. Ophthalmic Epidemiol. 2013;20:155-158
  7. Ortwine JK, Kaye KS, Li J, Pogue JM. Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy. 2015;35:11-16
  8. Jain R, Murthy SI, Motukupally SR. Clinical outcomes of corneal graft infections caused by multi-drug resistant Pseudomonas aeruginosa. Cornea. 2014;33:22-26
  9. Chatterjee S, Agrawal D. Multi-drug resistant Pseudomonas aeruginosa keratitis and its effective treatment with topical colistimethate. Indian J Ophthalmol. 2016;64:153-157
  10. Fernandes M, Vira D, Medikonda R, Kumar N. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome. Graefes Arch Clin Exp Ophthalmol. 2016;254:315-322
  11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrugresistant, extensively drug- resistant and pandrug-resistant bacteria: an international expert pro- posal for interim standard definitions for acquired resistance. Clin Microbiol Inf 2012;18:268-281
  12. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebe